Genfit S.A. (GNFT)
Euronext Paris · France · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 10.58 |
|---|---|
| 52-week range | 3.40 – 15.48 |
| Return, 1 month / 3 months | +18.6% / −22.4% |
| Return, 1 year / 3 years | +188.6% / +250.3% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 59 |
| Volatility (1 year) | 62.8% |
| Worst drawdown (1 year) | -46.6% |
| Average daily value traded | 3.78M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Genfit is a biopharmaceutical company based in France that focuses on metabolic and liver diseases. It develops small-molecule drug candidates that act on nuclear receptors and related biological pathways, with its main programmes aimed at cholestatic and other chronic liver conditions. The company also works on diagnostic approaches for liver disease, often in partnership with other firms. Its customers and collaborators are mainly healthcare professionals, hospitals and pharmaceutical partners involved in treating patients with liver disorders.
On this site Genfit S.A. appears as a stock on the Euronext Paris (France), code GNFT, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Genfit S.A. (GNFT) trades on the Euronext Paris in France. It last closed at EUR 10.58 on 27 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 184 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 188.6% and over the last three months it fell 22.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 76 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 7.1% | ||
| From 52-week high | -27.8% | ||
| Momentum | 70 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -22.4% | ||
| 6-month return | 30.1% | ||
| 12-month return, skipping the last month | 143.3% | ||
| Stability (higher is calmer) | 29 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 62.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.6% | ||
| Liquidity | 87 · Strong | Trades actively. | |
| Average daily value traded | 3.78M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +17.6% |
|---|---|
| 1 month | +18.6% |
| 3 months | −22.4% |
| 6 months | +30.1% |
| 1 year | +188.6% |
| 3 years | +250.3% |
| 5 years | +241.3% |
Signals
| 50-day / 200-day average | 11.11 / 9.88 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.69 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.